Demographic, reproductive and socioeconomic risk factors for cervical cancer in associ ati on with cytological and histopathological findings
Authors:
K. Brányik
Published in the journal:
Prakt Gyn 2008; 12(3): 162-170
Práce je převzata z časopisu Praktická gynekológi a, 2007; 14(2): 69– 79 na základě spolupráce redakcí našich časopisů a dohody o výměně odborných prací.
Summary
Cervical cancer is one of the most frequent carcinomas in women. Various subtypes of human papilloma virus (HPV 16, 18, 31, 33), environmental, demographic, reproductive risk factors (early sexu al intercourse, promiscuity, smoking, contraception, immunodeficiency, AIDS, insufficient nourishment, low socioeconomic status, sexu ally transmitted diseases) increase the risk of development of the disease. The aim of the study was to transfer theoretical knowledge into clinical practice and to assess the impact of several selected risk factors on the incidence and character of premalignant lesions in Slovak women. Using correlation analyses we found a significant linkage between selected risk factors and the development of cervical carcinoma (Tab. 2, Fig. 18) [31].
Key words:
carcinoma – cytology – biopsy – cervix – risk factors
Zdroje
1. Anton M, Horký M, Bláha O. The role of tumour suppressors and viral oncoproteins in cervical carcinogenesis. Ceska Gynekol 2000; 65(4): 275– 278.
2. Black PE, Brown EA. Spontaneous regression of carcinoma of the cervix: report of a case. J Maine Med Assoc 1959; 50: 358– 361.
3. Chabada J, Horváth A, Sílešová J et al. Prínos preventívnych gynekologických prehliadok k diagnostike a liečbe cervixových lézi í. Cs Gynek 1989; 54: 532– 533.
4. Chargui R, Damak T, Khomsi F et al. Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol 2006; 194(1): 43– 48.
5. Danaei G, Vander Ho orn S, Lopez AD et al. Comparative Risk Assessment collaborating group (Cancers). Ca uses of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005; 366(9499): 1784– 1793.
6. Fujiwaki R, Sawada K. Spontaneous regression in recurrent epithelial ovarian cancer. Arch Gynecol Obstet 2007; 275(5): 389– 391.
7. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol Oncol 2000; 78(3 Pt 2): S1– S13.
8. Horii R, Akiyama F, Kasumi F et al. Spontaneous „healing“ of breast cancer. Breast Cancer 2005; 12(2): 140– 144.
9. Klačko M. Prognóza pacientky s karcinómom krčka maternice. Slov Gynek Pôrod 2004; 11(4): 197– 191.
10. Kurillová L, Šimko J, Capiková D et al. Prvé skúsenosti s využitím polymerázovej reťazovej reakcie (PCR) pri detekcii a typizácii HPV infekcie u gynekologických pacientok s cervixovými léziami. Slov Gynek Pôrod 2004; 11: 55– 59.
11. Masák L. Štandardné postupy pri liečbe karcinómu krčka maternice. Gynekol prax 2003; 3(1): 26– 29.
12. Moscicki AB, Shiboski S, Hills NK et al. Regression of low- grade squ amous intra- epithelial lesions in young women. Lancet 2004; 364(9446): 1678– 1683.
13. Orr JW Jr. Radical hysterectomy: lessons in risk reduction. Gynecol Oncol 2001; 81(2): 129– 132.
14. Orr JW, Roland PY, Orr PJ et al. Subspecialty training: does it affect the outcome of women treated for a gynecologic malignancy? Curr Opin Obstet Gynecol 2001; 13(1): 1– 8.
15. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74– 108.
16. Potančok B, Sadovský O. Manažment prekanceróz maternicového krčka. Gynekol prax 2003; 1: 9– 15.
17. Redecha M, Korbeľ M, Nižňanská Z. Výskyt karcinómu maternicového krčka na Slovensku v rokoch 1990 – 2000. Gynekol prax 2004; 2(2): 118–124.
18. Redecha M, Korbeľ M, Redecha M. Karcinóm krčka maternice a HPV infekcia. Cesk Onkol 2006; 1(4): 234–238.
19. Rock CL, Michael CW, Reynolds RK, Ruffin MT. Prevention of cervix cancer. Crit Rev Oncol Hematol 2000; 33(3): 169– 185.
20. Sadovský O, Potančok B, Štefanovič J et al. Nová medzinárodná kolposkopická terminológia a jej slovenská verzia. Prakt Gynek 2004; 11: 12– 15.
21. Saslow D, Castle PE, Cox JT et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 2007; 57(1): 7– 28.
22. Schlecht NF, Platt RW, Du arte- Franco E et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003; 95(17): 1336– 1343.
23. Sivoňová M, Matáková T, Dobrota D, Kliment J. Vzťah medzi genetickými polymorfizmami glutati ón- S- transferáz a karcinómom prostaty. Klin Urol 2003; 2(3): 173– 175.
24. Solomon D, Davey D, Kurman R et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287(16): 2114– 2119.
25. Spriggs AI, Boddington MM. Progression and regression of cervical lesions. Review of smears from women followed without initial biopsy or treatment. J Clin Pathol 1980; 33(6): 517– 522.
26. Sviracevic B, Cuk D, Vuleta D, Sedlar S. Premalignant and malignant lesions of the uterine cervix- personal experience. Med Pregl 200; 53(7– 8): 378– 383.
27. Štefanovič J, Trupl J. Prínos detekcie papilomavírusovej infekcie v prevencii karcinómu krčka maternice. Prakt Gynek 2003; 10: 61– 64.
28. Zimmerman RK. HPV vaccine and its recommendations, 2007. J Fam Pract 2007; 56(2 Suppl Vaccines): S1– S5.
29. Zubor P, Kajo K, Dussan CA et al. Repetitive demand for radical cancer risk reduction surgery in a young BRCA1 mutation carrier with strong family history of BRCA linked malignancies. Ginekol Pol 2006; 77(7): 543– 549.
30. Žúbor P, Vojvodová A, Bartoš V et al. Genotyp HER- 2 a vplyv reprodukčných rizikových faktorov na vznik karcinómu prsníka. Slov Gynek Pôrod 2006; 13: 3– 8.
31. Žúbor P, Vojvodová A, Macháleková K et al. HER- 2 génový polymorfizmus a riziko karcinómu prsníka. Slov Gynek Pôrod 2006; 13: 58– 64.
Štítky
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicineČlánok vyšiel v časopise
Practical Gynecology
2008 Číslo 3
Najčítanejšie v tomto čísle
- Chronic vaginal dryness in oncology patients
- Particular characteristics of anorexia nervosa in adolescent girls
- Selektivní antagonista muskarinových M3 receptorů v léčbě hyperaktivního močového měchýře (overactive bladder, OAB) – darifenacin
- Prenatal preventi on of dental caries